# Dose Escalation and Pharmacokinetic Study of Paclitaxel Liposome Injection in Treating Patients With Advanced Solid Tumor After Failure From Conventional Treatments

> **NCT01994031** · PHASE4 · UNKNOWN · sponsor: **Nanjing Luye Sike Pharmaceutical Co., Ltd.** · enrollment: 36 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Paclitaxel liposome injection
- **DRUG:** Paclitaxel injection

## Key facts

- **NCT ID:** NCT01994031
- **Lead sponsor:** Nanjing Luye Sike Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-08
- **Primary completion:** 2015-07
- **Final completion:** —
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2014-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01994031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01994031, "Dose Escalation and Pharmacokinetic Study of Paclitaxel Liposome Injection in Treating Patients With Advanced Solid Tumor After Failure From Conventional Treatments". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT01994031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*